We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Biofortuna Reaches Key Milestones for ReadyPlex™
News

Biofortuna Reaches Key Milestones for ReadyPlex™

Biofortuna Reaches Key Milestones for ReadyPlex™
News

Biofortuna Reaches Key Milestones for ReadyPlex™

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Biofortuna Reaches Key Milestones for ReadyPlex™"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Biofortuna-reduced.png

Biofortuna Ltd has successfully achieved key milestones in the development of its new blood group genotyping product family – ReadyPlex™. This breakthrough has released the second tranche of its 2015 funding – totalling £1.5m – which will be used for final development and commercialisation of this innovative product line. The ReadyPlex range is aimed at the transfusion market, and will offer rapid genomic analysis of erythrocyte blood groups, human platelet antigens (HPAs), human neutrophil antigens (HNAs) and coagulation polymorphisms.

A product design freeze has now been achieved, and this additional funding – supported by all the company’s current investors, including Foresight VCTs, Catapult Ventures, Enterprise Ventures, Merseyside Special Investment Fund, private investors and management – will enable verification and validation of the product family as it moves towards clinical trials. In addition, the funding will be used to increase the capabilities and production capacity of Biofortuna’s manufacturing and development contract services division, helping to meet the demand of current and future contracts.

Dr Simon Douglas, Biofortuna CEO, said: “The new investment will be used to increase the portfolio of tests currently offered by Biofortuna. These new funds and the confidence of all of our investors shows the potential of Biofortuna as a leading diagnostic kit provider, as well as a world-class contract service manufacturer.”

Advertisement